Market Snapshot
  • U.S.
  • Europe
  • Asia
Ticker Volume Price Price Delta
DJIA 16,408.54 -16.31 -0.10%
S&P 500 1,864.85 2.54 0.14%
NASDAQ 4,095.52 9.29 0.23%
Ticker Volume Price Price Delta
STOXX 50 3,155.81 16.55 0.53%
FTSE 100 6,625.25 41.08 0.62%
DAX 9,409.71 91.89 0.99%
Ticker Volume Price Price Delta
NIKKEI 14,516.27 98.74 0.68%
TOPIX 1,173.37 6.78 0.58%
HANG SENG 22,760.24 64.23 0.28%

Today's Research on Mylan and Watson Pharmaceuticals: One Drug Maker's Sorrow is Another One's Joy



Today's Research on Mylan and Watson Pharmaceuticals: One Drug Maker's Sorrow
                             is Another One's Joy

  PR Newswire

  LONDON, January 18, 2013

LONDON, January 18, 2013 /PRNewswire/ --

The patent cliff has seen many drug majors lose their exclusivity on
blockbuster drugs to generic makers in the past years and this trend is
expected to go for some years to come. In 2012 alone, over 40 branded drugs
with a $35 billion yearly sales tag have lost patent protection. StockCall has
technical coverage on two of the biggest generic makers, Mylan Inc. (NASDAQ:
MYL) and Watson Pharmaceuticals Inc. (NYSE: WPI), which is available for free
upon registration at http://www.stockcall.com/report    

The generic drug industry has been feasting on patent expirations in recent
years, and if the start of 2013 is anything to go on, this year could see more
of the same. Major branded drug companies have lost exclusivity rights to a
number of top selling products, and generic alternatives, as well as
customer's pockets, have been the main beneficiaries.

Mylan only recently announced that it is now releasing its generic of Pfizer's
Dilantin tablets after receiving the FDA's seal of approval. Dilantin is given
for the control of generalized tonic-clonic (i.e., grand mal) and complex
partial (i.e., psychomotor, temporal lobe) seizures, and prevention and
treatment of seizures occurring during or following neurosurgery. According to
IMS Health, the 50 mg chewable tablet saw U.S. sales of close to $16.5 million
for a 12 month period ending September 30, 2012. See our technical analysis on
Mylan by sign up now at http://www.StockCall.com/MYL011813.pdf

Also in news lately has been Watson Pharmaceuticals Inc.'s [ Free Analysis
Report on WPI ] ^[ ^(1) ^] generic version of Ferring Pharmaceuticals' Lysteda
tablet which received the FDA's approval even as an infringement lawsuit
against Watson Pharma has been filed by the original maker of the drug. Whilst
this legal battle is still pending, Watson Pharma intends to make the most of
the time to launch its generic version. Last year, Lysteda saw revenues of
close to $25 million in the U.S.

Generic companies also currently have an impressive list of abbreviated new
drug applications awaiting FDA approval. Those that have first-to-file status
have the potential to be even more lucrative as these companies can enjoy a
period of generic exclusivity that is usually 180 days.  

Select generic drug makers have been focusing on expansion of late, in an
attempt to grow sales and profits. Some have been acquiring competitors, while
others have been investing in growing their presence abroad. Regardless,
generic drug companies appear to be in a strong position to grow in 2013.

Footer:

 1. Watson Pharmaceuticals Inc. Technical Analysis [
    http://www.StockCall.com/WatsonPharmaceuticalsInc011813.pdf ]

About StockCall.com

StockCall.com is a financial website where investors can have easy, precise
and comprehensive research and opinions on stocks making the headlines. Sign
up today to talk to our financial analyst at http://www.stockcall.com  

Contact: William T. Knight,: info@stockcall.com, +1-646-396-9857 (9:00 am EST
- 01:30 pm EST)
Sponsored Links
Advertisement
Advertisements
Sponsored Links
Advertisement